ABOUT THE 13TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
Back for its 13th annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. The forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities, and 20+ pitches by seed companies and during our Rising Stars session. We expect over 350 delegates to attend the event. The forum will provide a number of networking opportunities via our online One-2-One meeting systemwhich allows you to pre-book meetings with all the attendees at the dedicated meeting facilities. We anticipate more than 1700 face-to-face meetings to take place throughout 2 days.
Plenary Sessions will Include:
Global Outlook for Biopharma in 2020 Panel
Latest Trends in Private Equity & VC Panel
Pharma DealMakers Roundtable
CEO Vision Debate
China Partnering & Investment Panel
Early Stage Investor Roundtable
Rising Stars: Global Seed Session
Therapeutic Panels Include:
Advances in C&G Therapies Panel
Neuroscience BD&L Panel
Autoimmune & Inflammatory Diseases Panel
Oncology Advanced Therapies & Diagnostics Panel
Platform Technologies & Novel Therapeutics Panel
Oncology DealMaking Panel
Confirmed Keynote Speeches by:
"Recent trends in Global Pharma M&A and BD&L" by Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG
Thibaut Roulon, Investment Director, Life Sciences Investments, Bpifrance
Thilo Schroeder, Partner, Nextech Invest Ltd.
Thomas Schall, President and CEO, ChemoCentryx, Inc.
Tim Haines, Chairman & Managing Partner, Abingworth LLP
Tim Luker, VP, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly and Company
Vanela Bushi, Director, Portfolio Strategy & Transactions, Syneos Health
Vishal Doshi, Founder & CEO, AUM Biosciences
Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
Yuwen Liu, Founding Partner, BOHE Angel Fund
More TBA shortly...
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.
Presenters at the 13th ELSF Forum Include:
Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at 13th Annual European Life Sciences CEO Forum is an effective way to gain leads, introduce new products and services, expand sales, and build relationships. Exhibition space is very limited - express your interest to secure the area.
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on + 44 (0)203 463 4890 or by email: Silvia.
FINANCIAL, ADVISORY, INVESTORS ATTENDING: AbbVie Ventures Abingworth LLP Acceleris Capital Limited ACXIT Capital Management GmbH Aglaia BioMedical Ventures Alta Life Sciences Altitude Investment Management, LLC Apollo Ventures Arix Bioscience Plc. ARTO AG Asklepios Advisors ATGN Consulting Banca del Ceresio BB Pureos Bioventures Bellevue Asset Management AG Bergmann zur Hausen & Cie. GmbH Berlin Partner for Business and Technology GmbH BERNINA BioInvest Ltd BioGeneration Ventures BioMedPartners AG Bioqube Ventures BioScience Managers Pty Ltd. BioStart Consulting GmbH BOHE Angel Fund Bootstrap Europe Bpifrance Breslin AG BROTHERS & PARTNERS EUROPE Bryan, Garnier & Co Capital Grand Est Capricorn Partners NV CoFeS China Ltd. Coparion GmbH & Co. KG Deepbridge Capital LLP Delin Ventures Ltd. Deutsche Bank E.Gutzwiller & Cie, Banquiers Earlybird Venture Capital Edison Investment Research, Inc. Emerging Technology Partners, LLC (ETP) ErfindungsVerwertung AG (EVA) Ernst & Young AG European Investment Bank European Investment Fund FastVentures B.V. Ferghana Partners Fraser Finance LLP FutuRx Genextra S.p.A. Gimv GL Capital Group GLSV GmbH H.C. Wainwright & Co., LLC Hadean Ventures HBM Partners AG Heal Capital HealthCare Royalty Partners High-Tech Gründerfonds Management GmbH Indaco Venture Partners SGR SpA Industrifonden Inkef Capital B.V. Innogest Capital Inserm Transfert Initiative / Sofimac IPF Partners Jefferies Joint Polish Investment Fund Julius Baer Ltd. Kempen & Co Kreos Capital Management (UK) Ltd. LBBW Venture Capital Life Science Investments & Solutions GmbH LifeCare Partners LifeSci Advisors Lightstone Ventures Locust Walk Lombard Odier